A Phase 2 Trial Testing ZP1848 in Patients With SBS
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
A proof-of-concept, dose finding, controlled, single-center, randomized, double-blind, fixed
dose phase 2 trial with ZP1848 in patients with Short Bowel Syndrome.